Last edition
News about "MRSA infection"
Armata Pharmaceuticals Receives FDA Fast Track Designation for AP-SA02 Bacteriophage Therapy
The FDA has granted Fast Track designation to Armata’s AP-SA02 therapy for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA and MRSA infections.
MRSA Infection | 07/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members